论文部分内容阅读
测定了18例前列腺癌和50例前列腺增生症（BPH）患者的血浆前列腺特异性抗原（PSA）和前列腺特异性抗原密度（PSAD），同时随访观察治疗后血浆PSA水平变化。结果表明，在区别前列腺增生症和前列腺癌中，PSAD显著优于PSA，但应用于个体时要综合分析。治疗后进行血浆PSA观察对于早期发现前列腺癌局部复发和转移以及判断治．疗效果有重要价值。
Prostatic specific antigen (PSA) and prostate specific antigen density (PSAD) were measured in 18 cases of prostate cancer and 50 cases of benign prostatic hyperplasia (BPH). Plasma PSA levels were also observed after treatment. The results show that PSAD is significantly superior to PSA in distinguishing between benign prostatic hyperplasia and prostate cancer, but should be analyzed comprehensively when applied to individuals. Post-treatment plasma PSA observation for the early detection of local recurrence and metastasis of prostate cancer and determine the treatment. Therapeutic effect has important value.